For over 14 years, Biognosys has been driving progress and innovation in proteomics. Our proprietary next-generation proteomics technology is built on solid science, with over 2,400 publications featuring Biognosys’ workflows and products. In addition, multiple patents and exclusive licenses protect our unique technology and workflows.
Scientific excellence is the foundation of our cutting-edge proteomics solutions, providing multi-dimensional insights on protein expression, function, and structure at industry leading speed and scale across all major biological species and sample types.
Our proprietary Discovery Proteomics technology enables unprecedented proteome coverage and sample throughput for the simultaneous quantification of thousands of proteins across thousands of samples.
Limited Proteolysis Mass Spectrometry (LiP-MS) is a unique, patented technology for drug target identification and validation that enables a holistic understanding of the mechanism of action and binding mechanisms.
Our discovery proteomics workflow enables the quantification of complete proteomes, utilizing our proprietary, patented Hyper Reaction Monitoring (HRM™) technology.
HRM™ is a Data Independent Acquisition (DIA) based protein quantification workflow developed by Biognosys, offering unmatched proteome coverage with reproducible and precise quantification of up to 13,000 proteins per sample. The workflow is label-free, meaning that the amount of proteins is determined relatively across many biological samples without chemical labeling. The HRM™ workflow is ideal for identifying differentially expressed proteins or highly multiplexed protein quantification on a proteome level.
As part of the HRM™ workflow, mass spectrometry data are acquired in DIA mode in a highly parallel process and analyzed by targeted analysis using reference spectra, a method also known as SWATH that was co-invented by Biognosys. HRM™ provides a comprehensive, peptide-level measurement of all detectable proteins in the sample, with high reproducibility of results.
The analysis step is performed by the most advanced algorithms employed in our Spectronaut® DIA software, including our in-house search algorithm, Pulsar, Artificial Intelligence (AI) and Machine Learning (ML) signal detection and data normalization based on our patented Indexed Retention Time (iRT) technology. The HRM™ approach is also extendable to post-translational modifications.
Check out the Tissue Biomarker Discovery, Biofluid Biomarker Discovery, Mechanism Of Action Studies, and Phospho Profiling Studies contract research services based on our Discovery Proteomics technology.
Check out our TrueDiscovery™ research services platform, with various applications for biomarker discovery, mechanism of action studies, immunopeptidome profiling, and phosphoproteome profiling, based on our discovery proteomics technology.
Access our publications on HRM™ in the Resources section.
LiP-MS is a chemoproteomics approach that enables unbiased profiling of structural protein changes across the entire proteome with a depth of coverage of up to 9,000 proteins in human cells. The change in structure or surface accessibility alters proteolytic cleavage kinetics during the LiP reaction, resulting in unique peptide signatures that can be probed using quantitative proteomics approaches such as HRM.
Biognosys applies the LiP-MS technology for drug target deconvolution, identifying and analyzing structure-specific proteolytic states induced by drug binding in cellular lysates in a label-free manner without prior drug modifications. Moreover, we leverage high-resolution limited proteolysis (HR-LiP), a targeted LiP approach, to validate a known target. The target protein can have a high molecular mass or membrane localization and be analyzed at full length in a near-native environment.
LiP-MS is a proprietary technology developed in collaboration with the inventor of LiP, Prof. Paola Picotti, at ETH Zurich. Biognosys has deployed Machine Learning to develop LiP-MS technology to expand its drug target deconvolution ability beyond simple target identification. The LiP-MS applications based on this enhanced approach include target ranking, prediction of binding sites, and proteome-wide discovery of induced structural changes.
Biognosys is the sole, exclusive provider of proteomics solutions based on the patented LiP-MS technology. Check out the Drug Target Deconvolution and Drug target Validation applications available via our TrueTarget™ research services platform.
Access key publications on LiP-MS in the Resources section.
Quantify and analyze protein expression with unparalleled precision, depth, and throughput with our HRM™ discovery proteomics technology via contract research or our Spectronaut® software and peptide kits.
Gain actionable insights on post-translational modifications such as protein phosphorylation, utilizing our HRM™ technology via our contract research or in-house proteomics software and kits. technologies via our contract research or in-house proteomics software and kits.
Profile structural protein changes unbiasedly across the whole proteome with our LiP-MS-based Drug Target Deconvolution and Validation services.
Biognosys’ innovative technology is featured in over 3,000 publications. Many of these publications are co-authored by Biognosys in high-impact, peer-reviewed journals.
Access our key technology publications in the Resources section.
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 738 20 40
US Offices
Biognosys Inc
1 Broadway, 5th Floor
Cambridge, MA 02142
United States
Phone: +1 617 366 2684
